The US Food and Drug Administration needs to make sure a backlog of overdue surveillance inspections that has been growing due to COVID-19 travel restrictions does not compromise its ability to conduct “high-risk” inspections going forward, a Government Accountability Office official says.
The agency also should more fully explore the use of alternatives to the on-site inspections the pandemic prevents it from...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?